MONOMERIC INSULIN ANALOG FORMULATIONS.
566/CAL/1996 (566/CAL/1996)
Filed on 1996-03-25
Publication date 2005-03-04
The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5% of the analog present in the suspension is in the dissolved state.
Applicant
Eli Lilly & Company.,
Lilly Corporate Center, City of Indianapolis, State of Indiana, U.S.A.
Inventor
1) Michael Rosario De Felippis 2) Bruce Hill Frank
International Information
Classification
C 07 K 14/62 | C 07 K 1/32